THE GROWTH HORMONE RELEASING HORMONE ANALOGUE, TESAMORELIN, DECREASES MUSCLE FAT AND INCREASES MUSCLE AREA IN ADULTS WITH HIV
THE GROWTH HORMONE RELEASING HORMONE ANALOGUE, TESAMORELIN, DECREASES MUSCLE FAT AND INCREASES MUSCLE AREA IN ADULTS WITH HIV
复制标题
DOI：
10.14283/jfa.2018.45
复制
发表时间：
2019-07-01
影响因子：
3.9
通讯作者：
Erlandson, Kristine M.
中科院分区：
文献类型：
--
作者：
Adrian, S.;Scherzinger, A.;Erlandson, Kristine M.
Background: Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue in people living with HIV, however, the effects on skeletal muscle fat and area are unknown. Objectives: The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality (density) and quantity (area). Design: Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials. Setting: U.S. and Canadian sites. Participants: People living with HIV and with abdominal obesity. Tesamorelin participants were restricted to responders (visceral adipose tissue decrease >= 8%). Intervention: Tesamorelin or placebo. Measurements: Computed tomography scans (at L4-L5) were used to quantify total and lean density (Hounsfield Units, HU) and area (centimeters(2)) of four trunk muscle groups using a semi-automatic segmentation image analysis program. Differences between muscle area and density before and after 26 weeks of tesamorelin or placebo treatment were compared and linear regression models were adjusted for baseline and treatment arm. Results: Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%). In models adjusted for baseline differences and treatment arm, tesamorelin was associated with significantly greater increases in density of four truncal muscle groups (coefficient 1.56-4.86 Hounsfield units; all p
